- Home
- ADAP vs PYXS Comparison
ADAP vs PYXS Comparison
Compare ADAP & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- PYXS
- Stock Information
- Founded
- ADAP 2008
- PYXS 2018
- Country
- ADAP United Kingdom
- PYXS United States
- Employees
- ADAP N/A
- PYXS N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- PYXS Health Care
- Exchange
- ADAP Nasdaq
- PYXS Nasdaq
- Market Cap
- ADAP 75.5M
- PYXS 75.0M
- IPO Year
- ADAP 2015
- PYXS 2021
- Fundamental
- Price
- ADAP $0.08
- PYXS $1.10
- Analyst Decision
- ADAP Hold
- PYXS Strong Buy
- Analyst Count
- ADAP 6
- PYXS 5
- Target Price
- ADAP $1.02
- PYXS $9.00
- AVG Volume (30 Days)
- ADAP 18.4M
- PYXS 387.8K
- Earning Date
- ADAP 08-11-2025
- PYXS 08-13-2025
- Dividend Yield
- ADAP N/A
- PYXS N/A
- EPS Growth
- ADAP N/A
- PYXS N/A
- EPS
- ADAP N/A
- PYXS N/A
- Revenue
- ADAP $179,639,000.00
- PYXS N/A
- Revenue This Year
- ADAP N/A
- PYXS N/A
- Revenue Next Year
- ADAP $38.72
- PYXS N/A
- P/E Ratio
- ADAP N/A
- PYXS N/A
- Revenue Growth
- ADAP 878.53
- PYXS N/A
- 52 Week Low
- ADAP $0.08
- PYXS $0.83
- 52 Week High
- ADAP $1.36
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- ADAP 25.83
- PYXS 43.52
- Support Level
- ADAP $0.08
- PYXS $1.12
- Resistance Level
- ADAP $0.36
- PYXS $1.38
- Average True Range (ATR)
- ADAP 0.02
- PYXS 0.08
- MACD
- ADAP -0.02
- PYXS -0.01
- Stochastic Oscillator
- ADAP 1.38
- PYXS 5.08
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.